Protein-based vaccine provides a new option.
After receiving approval from the Centers for Disease Control, the Food and Drug Administration cleared Novavax’s COVID-19 vaccine last week for emergency use in people aged 12 through 17. Though many of Novavax’s studies about their vaccine were conducted during the surge of COVID-19’s Delta variant, the White House says having another vaccine option will still be helpful in the current fight against Omicron variants and subvariants.
At the original release of Novavax, FDA Commissioner Robert Califf stated, “Authorizing an additional COVID-19 vaccine expands the available vaccine options for the prevention of COVID-19, including the most severe outcomes that can occur such as hospitalization and death.” He added, “COVID-19 vaccines remain the best preventive measure against severe disease caused by COVID-19.“
As the Lord Leads, Pray with Us…
- For wisdom for Commissioner Califf as he heads the FDA.
- For Director Walensky as she oversees the reorganizing of her agency in light of feedback regarding the pandemic.
- With gratitude to the Lord that the severity of the virus has continued to diminish.
Sources: Food and Drug Administration, The Hill
